Jelmyto

Cancer cells

Marketing

UroGen: This year 'critical for Jelmyto's success'

UroGen’s reformulated chemo drug Jelmyto faces a make-or-break year in 2022 as analysts mull its “considerable uncertainty.”

Ben Adams Mar 24, 2022 8:50am

UroGen undeterred after RTGel-Botox combo misses in phase 2

Sep 3, 2020 10:15am

Liz Barrett

UroGen gears up virtual launch as FDA clears Jelmyto chemo gel

Apr 16, 2020 11:36am